Preliminary Virtual Screening Studies to Identify GRP78 Inhibitors Which May Interfere with SARS-CoV-2 Infection.
Covid-19
GRP78
SARS-CoV-2
antiviral
gene expression
repurposed drugs
virtual screening
Journal
Pharmaceuticals (Basel, Switzerland)
ISSN: 1424-8247
Titre abrégé: Pharmaceuticals (Basel)
Pays: Switzerland
ID NLM: 101238453
Informations de publication
Date de publication:
25 Jun 2020
25 Jun 2020
Historique:
received:
26
05
2020
revised:
21
06
2020
accepted:
22
06
2020
entrez:
8
7
2020
pubmed:
8
7
2020
medline:
8
7
2020
Statut:
epublish
Résumé
SARS-CoV-2 Spike protein was predicted by molecular docking to bind the host cell surface GRP78, which was suggested as a putative good molecular target to inhibit Covid-19. We aimed to confirm that GRP78 gene expression was increased in blood of SARS-CoV-2 (+) versus SARS-CoV-2 (-) pneumonia patients. In addition, we aimed to identify drugs that could be repurposed to inhibit GRP78, thus with potential anti-SARS-CoV-2 activity. Gene expression studies were performed in 10 SARS-CoV-2 (-) and 24 SARS-CoV-2 (+) pneumonia patients. A structure-based virtual screen was performed with 10,761 small molecules retrieved from DrugBank, using the GRP78 nucleotide binding domain and substrate binding domain as molecular targets. Results indicated that GRP78 mRNA levels were approximately four times higher in the blood of SARS-CoV-2 (+) versus SARS-CoV-2 (-) pneumonia patients, further suggesting that GRP78 might be a good molecular target to treat Covid-19. In addition, a total of 409 compounds were identified with potential as GRP78 inhibitors. In conclusion, we found preliminary evidence that further proposes GRP78 as a possible molecular target to treat Covid-19 and that many clinically approved drugs bind GRP78 as an off-target effect. We suggest that further work should be urgently carried out to confirm if GRP78 is indeed a good molecular target and if some of those drugs have potential to be repurposed for SARS-CoV-2 antiviral activity.
Identifiants
pubmed: 32630514
pii: ph13060132
doi: 10.3390/ph13060132
pmc: PMC7345920
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Fundação para a Ciência e a Tecnologia
ID : PTDC/SAU-PUB/28736/2017
Références
IDrugs. 2010 Sep;13(9):636-45
pubmed: 20799147
Cell Stress Chaperones. 2016 Nov;21(6):1065-1076
pubmed: 27631331
Cell. 2020 Apr 16;181(2):281-292.e6
pubmed: 32155444
Pathogens. 2020 Apr 22;9(4):
pubmed: 32331255
Antiviral Res. 2017 Jun;142:158-168
pubmed: 28238876
Nature. 2020 May;581(7807):221-224
pubmed: 32225175
J Virol. 2020 Mar 17;94(7):
pubmed: 31996437
J Mol Cell Biol. 2020 May 18;12(4):322-325
pubmed: 32236562
Front Oncol. 2019 Dec 20;9:1453
pubmed: 31956604
Clin Cancer Res. 2017 Nov 1;23(21):6661-6672
pubmed: 28765324
Virol J. 2011 Mar 20;8:128
pubmed: 21418596
Carcinogenesis. 2014 Nov;35(11):2544-54
pubmed: 25194164
Antimicrob Agents Chemother. 2014 Aug;58(8):4885-93
pubmed: 24841273
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
BMC Cancer. 2008 Mar 10;8:70
pubmed: 18331622
Mol Cancer Ther. 2008 Oct;7(10):3129-40
pubmed: 18852116
J Clin Med. 2019 Oct 26;8(11):
pubmed: 31717752
Br J Cancer. 2013 Jul 23;109(2):433-43
pubmed: 23807168
Int J Antimicrob Agents. 2020 Jun;55(6):105969
pubmed: 32278811
PLoS One. 2016 May 04;11(5):e0154862
pubmed: 27144892
J Anesth. 2005;19(3):236-42
pubmed: 16032452
J Adv Res. 2020 Mar 16;24:91-98
pubmed: 32257431
In Vivo. 2020 Jun;34(3 Suppl):1645-1650
pubmed: 32503824
Life Sci. 2019 Jun 1;226:156-163
pubmed: 30978349
Virol J. 2019 May 27;16(1):69
pubmed: 31133031
Sci Rep. 2018 Apr 3;8(1):5487
pubmed: 29615633
J Virol. 2017 Feb 28;91(6):
pubmed: 28053106
Ann Pharmacother. 2019 Jun;53(6):612-620
pubmed: 30607980
Histol Histopathol. 2008 Nov;23(11):1409-16
pubmed: 18785123
J Med Chem. 2011 Jun 23;54(12):4034-41
pubmed: 21526763
Cancer Res. 2006 Sep 15;66(18):9260-9
pubmed: 16982771
Lung. 2019 Dec;197(6):827-828
pubmed: 31605157
Curr Top Med Chem. 2008;8(18):1555-72
pubmed: 19075767
Sci Rep. 2019 Dec 10;9(1):18742
pubmed: 31822716
J Virol. 2007 Oct;81(20):10981-90
pubmed: 17670839
Radiother Oncol. 2015 Sep;116(3):358-65
pubmed: 25981132
Expert Opin Investig Drugs. 2012 Mar;21(3):383-93
pubmed: 22242557
Antiviral Res. 2014 Sep;109:171-4
pubmed: 25017472
Rev Panam Salud Publica. 2020 Mar 20;44:e40
pubmed: 32256547
Nat Microbiol. 2020 Apr;5(4):536-544
pubmed: 32123347
J Biomol Struct Dyn. 2020 May 5;:1-10
pubmed: 32340551
Mol Biol Cell. 2014 Jul 1;25(13):2006-16
pubmed: 24829380
Structure. 2015 Dec 1;23(12):2191-2203
pubmed: 26655470
J Infect. 2020 May;80(5):554-562
pubmed: 32169481
Nat Commun. 2020 Mar 27;11(1):1620
pubmed: 32221306
J Biol Chem. 2010 May 14;285(20):15065-75
pubmed: 20208072
Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6
pubmed: 18048412
Science. 2020 May 22;368(6493):829-830
pubmed: 32385101
Sci Rep. 2019 Jul 3;9(1):9595
pubmed: 31270381
J Phys Chem Lett. 2020 Jun 18;11(12):4785-4790
pubmed: 32463239
Lancet. 2020 Jun 13;395(10240):1820
pubmed: 32511943
Cell Death Dis. 2014 May 22;5:e1240
pubmed: 24853418
Onco Targets Ther. 2019 Jan 18;12:635-645
pubmed: 30705592
Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082
pubmed: 29126136
J Virol. 2002 Jan;76(2):633-43
pubmed: 11752154
Drugs Today (Barc). 2019 Apr;55(4):231-236
pubmed: 31050691